乳腺癌组织中AIB-1蛋白表达与临床病理指标的相关性

目的探讨乳腺癌组织中AIB-1的表达与临床病理指标的关系。方法采用免疫组织化学方法检测218例乳腺癌组织、45例正常乳腺组织、45例良性乳腺病变组织中AIB-1表达情况，并结合乳腺癌患者的临床病理资料进行统计分析。结果乳腺癌组织中AIB-1过表达率（54.59％）显著高于正常乳腺组织（22.22％）和乳腺良性病变组织（33.33％）（P=0.000）。AIB-1在乳腺癌组织学分级Ⅲ级组过表达率（63.39％）显著高于Ⅰ级组（18.18％）和Ⅱ级组（48.42％）（P=0.004）。AIB-1在腋淋巴结转移＞3个组中的过表达率（73.47％）显著高于腋淋巴结转移≤3个组（49.11％）（P=0.003）。乳腺癌组织中，AIB-1过表达率在ER阳性组（59.26％）、阴性组（46.99％）间的差异无统计学意义（P=0.077），PR阳性组（59.48％）、阴性组（49.02％）间的差异无统计学意义（P=0.122），而HER-2阳性组的AIB-1过表达率（64.08％）显著高于阴性组（46.08％）（P=0.008）。结论乳腺癌中AIB-1过表达与肿瘤的恶性程度密切相关，提示可能预后不良。AIB-1是一个重要的预测他莫昔芬疗效的指标。

Expression of Nuclear Receptor Coactivators AIB-1 and Relationship with Clinical-patho-logical Features in Breast Cancer

Objective To investigate the expression of nuclear receptor coactivators AIB-1 and the relationship and clinical meaning with the clinical pathological features in breast cancer. Methods The study included 218 cases with breast cancers, 45 cases of normal breast tissue and 45 cases with benign lesions of breast.Using immunohistochemistry, we examined the expression of AIB-1 in all cases. Patients’ age, the state of menstruation, the size of tumors, clinical stages, pathological types, histological grades, the metastatic state of the axillary lymph nodes, ER, PR and HER-2 of all the breast cancer patients had been sorted to be analyzed. Results Among breast cancers(54.59％) ，benign lesions(33.33%) and normal breast tissues(22.22%), the overexpressions rate of AIB-1 protein in three groups above showed significant difference (P＝0.000) . The overexpression rate of AIB-1 protein in grade Ⅲ(63.39%) was higher than these in grade Ⅰ(18.18%) and in grade Ⅱ(48.42%) (P=0.004) . The overexpression rate of AIB-1 protein in the cases that the number of the metastatic axillary lymph nodes was more than three (73.47%) ,which was higher than the others (49.11%) (P=0.003) . In the cases with breast cancers,the overexpression rate of AIB-1 had no correlation with ER and PR(P＞0.05). But the overexpression rate of AIB-1 was higher in patients with HER-2(+)(64.08%) than that in patients with HER-2(-)(46.08%) (P=0.008). Conclusion In the cases with breast cancers, the overexpression of AIB-1 may correlate with the clinical phenotype and biology of breast cancer as well as poor prognosis.